metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population 9
mML - NA - PDL1 positive 1
mML - 1st line (L1)
mML - L1 - all population 7
mML - L1 - BRAF mutant 2
mML - L1 - BRAF wild 3
mML - 2nd line (L2)
mML - L2 - all population 11
mML - L2 - BRAF mutant 1
mesothelioma (MS)

immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
atezolizumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab followed by ipilimumab
Immune checkpoint association
nivolumab plus ipilimumab
relatlimab plus nivolumab

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs ipilimumab plus dacarbazine
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

RELATIVITY-047, 0 NCT03470922

relatlimab plus nivolumab (n=-9) vs. nivolumab alone (n=-9)

randomized controlled trial

Studied treatment

relatlimab plus nivolumab
single fixed-dose intravenous (IV) infusion of 160 mg of relatlimab plus 480 in a fixed-dose coombination or 480 mg of IV nivolumab every 4 weeks.

Control treatment

nivolumab
480 mg of IV nivolumab every 4 weeks.

Patients

mML - L1 - all population

Method

double blind

at 111 sites in North America, Central America, South America, Europe, Australia, and New Zealand

P2-3 /

Remark

powered by vis.js Network